-
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US6036931029 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 6.25 |
| PE Ratio | None |
| Market Cap | 77M |
| Beta | nan |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for INKT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024